International Biotechnology (LON:IBT) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

International Biotechnology (LON:IBT)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 684.42 ($8.33) and traded as high as GBX 703.25 ($8.56). International Biotechnology shares last traded at GBX 702 ($8.54), with a volume of 145,383 shares.

International Biotechnology Stock Down 0.9 %

The firm has a market cap of £256.50 million, a price-to-earnings ratio of 1,445.83 and a beta of 0.21. The stock has a 50-day moving average of GBX 694.71 and a 200-day moving average of GBX 684.87. The company has a current ratio of 0.46, a quick ratio of 0.32 and a debt-to-equity ratio of 9.66.

International Biotechnology Increases Dividend

The company also recently declared a dividend, which will be paid on Friday, January 24th. Stockholders of record on Thursday, December 19th will be given a dividend of GBX 15.56 ($0.19) per share. The ex-dividend date of this dividend is Thursday, December 19th. This represents a dividend yield of 2.21%. This is a positive change from International Biotechnology’s previous dividend of $14.50. International Biotechnology’s dividend payout ratio is currently 6,041.67%.

Insider Buying and Selling

In other International Biotechnology news, insider Katherine Cornish-Bowden purchased 1,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average price of GBX 713 ($8.68) per share, with a total value of £10,695 ($13,012.53). Corporate insiders own 4.18% of the company’s stock.

About International Biotechnology

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.